Abstract:COVID-19 is characterised by a broad spectrum of clinical and pathological features. Natural killer (NK) cells play an important role in innate immune responses to viral infections. Here, we analysed the phenotype and activity of NK cells in the blood of COVID-19 patients using flow cytometry, single-cell RNA-sequencing (scRNA-seq), and a cytotoxic killing assay. In the plasma of patients, we quantified the main cytokines and chemokines. Our cohort comprises COVID-19 patients hospitalised in a low-care ward unit (WARD), patients with severe COVID-19 disease symptoms hospitalised in intensive care units (ICU), and post-COVID-19 patients, who were discharged from hospital six weeks earlier. NK cells from hospitalised COVID-19 patients displayed an activated phenotype with substantial differences between WARD and ICU patients and the timing when samples were taken post-onset of symptoms. While NK cells from COVID-19 patients at an early stage of infection showed increased expression of the cytotoxic molecules perforin and granzyme A and B, NK cells from patients at later stages of COVID-19 presented enhanced levels of IFN-γ and TNF-α which were measured ex vivo in the absence of usual in vitro stimulation. These activated NK cells were phenotyped as CD49a + CD69a + CD107a + cells, and their emergence in patients correlated to the number of neutrophils, and plasma IL-15, a key cytokine in NK cell activation. Despite lower amounts of cytotoxic molecules in NK cells of patients with severe symptoms, majority of COVID-19 patients displayed a normal cytotoxic killing of Raji tumour target cells. In vitro stimulation of patients blood cells by IL-12+IL-18 revealed a defective IFN-γ production in NK cells of ICU patients only, indicative of an exhausted phenotype. ScRNA-seq revealed, predominantly in patients with severe COVID-19 disease symptoms, the emergence of an NK cell subset with a platelet gene signature that we identified by flow and imaging cytometry as aggregates of NK cells with CD42a + CD62P + activated platelets. Post-COVID-19 patients show slow recovery of NK cell frequencies and phenotype. Our study points to substantial changes in NK cell phenotype during COVID-19 disease and forms a basis to explore the contribution of platelet-NK cell aggregates to antiviral immunity against SARS-CoV-2 and disease pathology.

Natural killer cell immunotypes related to COVID-19 disease severity

Severe COVID-19 patients display hyper-activated NK cells and NK cell-platelet aggregates

Elevated levels of cell-free NKG2D-ligands modulate NKG2D surface expression and compromise NK cell function in severe COVID-19 disease

Flattening the COVID-19 Curve With Natural Killer Cell Based Immunotherapies

CD151 identifies an NK cell subset that is enriched in COVID-19 patients and correlates with disease severity

The HLA-B –21 M/T dimorphism associates with disease severity in COVID-19

Longitudinal transcriptional changes reveal genes from the natural killer cell-mediated cytotoxicity pathway as critical players underlying COVID-19 progression

Elevated Exhaustion Levels of NK and CD8+ T Cells as Indicators for Progression and Prognosis of COVID-19 Disease

Natural Killer Cell Dysfunction and Its Role in COVID-19

NK Cell–Monocyte Cross-talk Underlies NK Cell Activation in Severe COVID-19

NK cell receptor and ligand composition influences the clearance of SARS-CoV-2

Exploring the Utility of NK Cells in COVID-19

Innate immune response in COVID-19: single-cell multi-omics profile of NK lymphocytes in a clinical case series

MAIT cell activation and dynamics associated with COVID-19 disease severity

Natural killer cells play an important role in virus infection control: Antiviral mechanism, subset expansion and clinical application

Interferon-mediated NK cell activation is associated with limited neutralization breadth during SARS-CoV-2 infection

Unique immunological profile in patients with COVID-19

SARS-CoV-2 modulates NK cell responses via induction of HLA-E and triggers expansion of adaptive NK cells during acute infection

Identification of Distinct Immune Cells Associated with Various Clinical Presentations of COVID-19

Immunometabolic features of natural killer cells are associated with infection outcomes in critical illness